Compare Essex Property Trust, Inc. (ESS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs BIO-TECHNE Corp — how do they compare? Essex Property Trust, Inc. trades at $269.13 (market cap $17.26B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Essex Property Trust, Inc. is the larger of the two by market cap, and Essex Property Trust, Inc. pays the higher dividend (3.86%). Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and BIO-TECHNE Corp for 63 Days on average.
| ESS | TECH | |
|---|---|---|
Market Cap | $17.26B | $11.36B |
Volume | 454,464 | 5,390,331 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $72.61 |
52-Week Low | $239.61 | $43.31 |
Typical Hold Time | 111 Days | 63 Days |
Enterprise Value | $23.86B | $11.39B |
Dividend Yield | 3.86% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.05, down 1.63% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue reached $1.89B in 2025, with a net income margin of 21.48%, while valuation ratios like a P/E of 41.83 suggest a premium. Recent news highlights strong Q2 2026 results, raised guidance, and a declared dividend of $2.59 per share.
The outlook is cautiously optimistic, supported by operational strength and resolved litigation, but high valuation and earnings volatility pose risks. Analyst consensus is a Buy with a $303.41 price target, indicating potential upside, though investors should monitor debt levels and consistent earnings delivery against expectations.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
